ImmuneOnco Biopharma
Dedicated to the development and commercialization of novel cancer immunotherapy products designed to reverse cancer cell-induced immune inhibition and to actively eradicate cancer cells.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
* | N/A | $30.0m | IPO |
| Total Funding | 000k | ||
| CNY | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (89 %) | (28 %) | 19110 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (14233 %) | (71467 %) | (85787 %) | (377 %) |
| Profit | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (14465 %) | (74887 %) | (98305 %) | (426 %) |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 3473 % | 51551 % | 75633 % | 435 % |
Source: Company filings or news article
Related Content
ImmuneOnco Biopharma, founded in June 2015 in Zhangjiang High Tech Park of Shanghai, China, is an early-stage biotechnology company focused on developing innovative therapies for cancer and viral infections. The company leverages advanced platforms that utilize two types of innate immune cells to achieve its therapeutic goals.
ImmuneOnco operates in the biopharmaceutical market, serving clients such as healthcare providers, research institutions, and pharmaceutical companies. Its business model revolves around the research and development of novel biological medicines, with a particular emphasis on natural killer (NK) cells, which are crucial for the body's defense against diseases. The company generates revenue through partnerships, licensing agreements, and potential future sales of its proprietary therapies.
Keywords: biopharma, cancer therapy, viral infections, innate immune cells, NK cells, biotechnology, Shanghai, early-stage, biological medicines, research and development.